Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis

Brain

Volumn 125, Issue 10, 2002, Pages 2342-2352

  Chard, D T ^a   Griffin, C M ^a   McLean, M A ^b   Kapeller, P ^c   Kapoor, R ^a   Thompson, A J ^a   Miller, D H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EPILEPSY SOCIETY   (United Kingdom)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Grey matter; Metabolite concentrations; Multiple sclerosis; Normal appearing white matter; Proton magnetic resonance spectroscopic imaging

Indexed keywords

CHOLINE DERIVATIVE; CREATINE; CREATINE PHOSPHATE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID;

ADULT; ARTICLE; BRAIN METABOLISM; BRAIN SIZE; CONTROLLED STUDY; FEMALE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; MULTIPLE REGRESSION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RELAPSE; WHITE MATTER;

EID: 0036788493     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awf240     Document Type: Article

References (69)

1. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979; 41: 81-91.
2. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. [Review]. Neuroimage 2000; 11: 805-21.
3. Bakshi R, Ariyaratana S, Benedict RH, Jacobs L. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch Neurol 2001; 58: 742-8.
4. Bhakoo KK, Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 2000; 74: 254-62.
5. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999; 20: 1619-27.
6. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901.
7. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001; 57: 1248-52.
8. Bjartmar C, Battistuta J, Terada N, Dupree E, Trapp BD. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 2002; 51: 51-8.
9. Bluml S, Seymour KJ, Ross BD. Developmental changes in choline- and ethanolamine-containing compounds measured with proton-decoupled (31)P MRS in in vivo human brain. Magn Reson Med 1999; 42: 643-54.
10. Bo L, Nyland H, Vedeler C, Trapp BD, Mork SJ. Extensive cortical demyelination in multiple sclerosis brains [abstract]. Rev Neurol (Paris) 2000; 156 Suppl 3: S25.
11. Boggild MD, Williams R, Haq N, Hawkins CP. Cortical plaques visualised by fluid-attenuated inversion recovery imaging in relapsing multiple sclerosis. Neuroradiology 1996; 38 Suppl 1: S10-3.
12. Boulanger Y, Labelle M, Khiat A. Role of phospholipase A(2) on the variations of the choline signal intensity observed by 1H magnetic resonance spectroscopy in brain diseases. [Review]. Brain Res Brain Res Rev 2000; 33: 380-9.
13. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993; 15: 289-98.
14. 1 relaxation times, and metabolite concentrations. J Neurol Neurosurg Psychiatry 2000; 68: 627-32.
15. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry 1962; 25: 315-20.
16. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93.
17. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125: 327-37.
18. Ciccarelli O, Giugni E, Paolillo A, Mainero C, Gasperini C, Bastianello S, et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 1999; 6: 455-9.
19. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-82.
20. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49-58.
21. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63: 736-42.
22. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995; 38: 901-9.
23. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121: 1469-77.
24. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70.
25. Demougeot C, Gamier P, Mossiat C, Bertrand N, Giroud M, Beley A, et al. N-acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. J Neurochem 2001; 77: 408-15.
26. Doyle TJ, Bedell BJ, Narayana PA. Relative concentrations of proton MR visible neurochemicals in gray and white matter in human brain. Magn Reson Med 1995; 33: 755-9.
27. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000; 47: 391-5.
28. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Administration and scoring manual for the multiple sclerosis functional composite measure (MSFC). New York: Demos; 1999.
29. Freund RJ, Wilson WJ. Problems with the model. In: Freund RJ, Wilson WJ, editors. Regression analysis: statistical modeling of a response variable. San Diego, CA: Academic Press; 1998. p. 229-69.
30. Fu L, Wolfson C, Worsley KJ, De Stefano N, Collins DL, Narayanan S, et al. Statistics for investigation of multimodal MR imaging data and an application to multiple sclerosis patients. NMR Biomed 1996; 9: 339-46.
31. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121: 103-13.
32. Glanville NT, Byers DM, Cook HW, Spence MW, Palmer FB. Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. Biochim Biophys Acta 1989; 1004: 169-79.
33. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box and-block and nine-hole peg tests. Arch Phys Med Rehabil 1988; 69: 850-4.
34. Grachev ID, Apkarian AV. Chemical heterogeneity of the living human brain: a proton MR spectroscopic study on the effects of sex, age, and brain region. Neuroimage 2000; 11: 554-63.
35. Gronwell DMA. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 1977; 44: 367-73.
36. Harada M, Miyoshi H, Otsuka H, Nishitani H, Uno M. Multivariate analysis of regional metabolic differences in normal ageing on localised quantitative proton MR spectroscopy. Neuroradiology 2001; 43: 448-52.
37. Kapeller P, McLean MA, Griffin CM, Chard D, Parker GJ, Barker GJ, et al. Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol 2001; 248: 131-8.
38. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34: 661-9.
39. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999; 122: 17-26.
40. Koopmans RA, Li DK, Zhu G, Allen PS, Penn A, Paty DW. Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products. Lancet 1993; 341: 631-2.
41. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
42. Lai M, Hodgson T, Gawne-Cain M, Webb S, MacManus D, McDonald WI, et al. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60: 339-41.
43. 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 1999; 246: 1023-6.
44. Leary SM, Brex PA, MacManus DG, Parker GJ, Barker GJ, Miller DH, et al. A (1)H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. Magn Reson Imaging 2000; 18: 455-9.
45. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
46. Mader I, Roser W, Kappos L, Hagberg G, Seelig J, Radue EW, et al. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol 2000; 21: 1220-7.
47. McLean MA, Woermann FG, Barker GJ, Duncan JS. Quantitative analysis of short echo time (1)H-MRSI of cerebral gray and white matter. Magn Reson Med 2000; 44: 401-11.
48. Miller DH, Rudge P, Johnson G, Kendall BE, MacManus DG, Moseley IF, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111: 927-39.
49. Molyneux PD, Tubridy N, Parker GJ, Barker GJ, MacManus DG, Tofts PS, et al. The effect of section thickness on MR lesion detection and quantification in multiple sclerosis. AJNR Am J Neuroradiol 1998; 19: 1715-20.
50. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43: 56-71.
51. Noworolski SM, Nelson SJ, Henry RG, Day MR, Wald LL, StarLack J, et al. High spatial resolution 1H-MRSI and segmented MRI of cortical gray matter and subcortical white matter in three regions of the human brain. Magn Reson Med 1999; 41: 21-9.
52. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389-400.
53. Plummer DL. Dispimage: a display and analysis tool for medical images. Rev Neuroradiol 1992; 5: 489-95.
54. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
55. Pouwels PJ, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med 1998; 39: 53-60.
56. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672-9.
57. 1H MRSI of normal appearing white matter in multiple sclerosis. Mult Scler 1997; 3: 231-7.
58. Rothman DL, Sibson NR, Hyder F, Shen J, Behar KL, Shulman RG. In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. [Review]. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1165-77.
59. Rovaris M, Rocca MA, Yousry I, Yousry TA, Colombo B, Comi G, et al. Lesion load quantification on fast-FLAIR, rapid acquisition relaxation-enhanced, and gradient spin echo brain MRI scans from multiple sclerosis patients. Magn Reson Imaging 1999; 17: 1105-10.
60. Rovaris M, Filippi M, Minicucci L, Iannucci G, Santuccio G, Possa F, et al. Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol 2000; 21: 402-8.
61. Sailer M, O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, McDonald WI, et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999; 52: 599-606.
62. 1H magnetic resonance spectroscopic imaging, Magn Reson Med 2001; 45: 899-907.
63. Sharma R, Narayana PA, Wolinsky JS. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler 2001; 7: 221-6.
64. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37-45.
65. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 2000; 6: 148-55.
66. Tourbah A, Stievenart JL, Gout O, Fontaine B, Liblau R, Lubetzki C, et al. Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis. Neurology 1999; 53: 1091-7.
67. 1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999; 46: 79-87.
68. Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med 1994; 31: 365-73.
69. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. [Review]. Physiol Rev 2000; 80: 1107-213.